Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of Trans-4-hydroxytamoxifen

Journal of the National Cancer Institute

Volumn 83, Issue 20, 1991, Pages 1477-1482

  Osborne, C Kent ^a   Coronado, Ester ^a   Allred, D Craig ^a   Wiebe, Valerie ^b   Degregorio, Michael ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; DRUG METABOLITE; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TISSUE LEVEL; FEMALE; GROWTH STIMULATION; HISTOLOGY; HUMAN; HUMAN CELL; ISOMERISM; MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMAL; BREAST NEOPLASMS; DRUG RESISTANCE; ESTROGENS; FEMALE; HUMAN; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIOIMMUNOASSAY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STEREOISOMERISM; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0026068370     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/83.20.1477     Document Type: Article

References (26)

1. Early Breast Cancer Trialists’ Collaborative Group; Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer An overview of 61 randomized trials among 28, 896 women. N Engl J Med 319:1681-1692, 1988
2. Saez RA, Osborne CK: Hormonal treatment of advanced breast cancer. In Current Clinical Oncology (Kennedy BJ, ed). New York: Alan R. Liss, 1989, pp 163-172
3. Jordan VC, Robinson SP, Welshons WV: Resistance to antiestrogen therapy. In Drug Resistance (Kessle D, ed). Boca Raton, Fla: CRC Press, 1987, pp 403-427
4. Buckley MM, Goa KL: Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 37:451-490, 1989
5. Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26:883-888, 1990
6. Hull DF III, Clark GM, Osborne CK, et al: Multiple estrogen receptor assays in human breast cancer. Cancer Res 43:413-416, 1983
7. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189-1196, 1987
8. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590, 1985
9. Grill HJ, Manz B, Pollow K: Double labelling assay system for oestrogen and progesterone receptors. Lancet 1:679, 1982
10. Siler-Khodr TM, Kuehl TJ, Vickery BH: Effects of a gonadotropin-releasing hormone antagonist on hormonal levels in the pregnant baboon and on fetal outcome. Fertil Steril 41:448-454, 1984
11. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988
12. Gottardis MM, Jiang SY, Jeng MH, et al: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989
13. Gottardis MM, Wagner RJ, Borden EC, et al: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49:4765-4769, 1989
14. Robertson DW, Katzenellenbogen JA, Long DJ, et al: Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem 16:1-13, 1982
15. Katzenellenbogen BS, Norman MJ, Eckert RL, et al: Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112-119, 1984
16. Osborne K, Coronado E, Wiebe V, et al: Acquired tamoxifen (Tarn) resistance in breast cancer correlates with reduced tumor accumulation of tarn and trans-4-hydroxytam (4HT). Proc ASCO 10:46, 1991
17. Katzenellenbogen JA, Carlson KE, Katzenellenbogen BS: Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: Limitations to the interpretation of experiments characterizing the activity of individual isomers. J Steroid Bio chem 22:589-596, 1985
18. Malet C, Gompel A, Spritzer P, et al: Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res 48:7193-7199, 1988
19. McCague R, Leclercq G, Jordan VC: Non-isomerizable analogues of (Z) and (E)-4-hydroxytamoxifen. Synthesis and endccrinological properties of substituted diphenylbenzocycloheptenes. J Med Chem 31:1285-1290, 1988
20. Pritchard KI, Thomson DB, Myers RE, et al: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787-796, 1980
21. Hoogstraten B, Gad-el-Mawla N, Maloney TR, et al: Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 54:2248-2256, 1984
22. Taylor SG IV, Gelman RS, Falkson G, et al: Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104:455-461, 1986
23. Lam HΥ: Tamoxifen is a calmodulin antagonist in the activation of CAMP phosphodiesterase. Biochem Biophys Res Commun 118:27-32, 1984
24. Su HD, Mazzei GJ, Vogler WR, et al: Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous Substrate proteins from the rat brain and ovary. Biochem Pharmacol 34:3649-3653, 1985
25. Clarke R, van den Berg HW, Murphy RF: Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17ß-estradiol. J Natl Cancer Inst 82:1702-1705, 1990
26. Murphy LC, Dotzlaw H: Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 3:687-693, 1989